Bioniche Provides Update on Refractory Bladder Cancer Trial

    - trial underway since November, 2006 -

    BELLEVILLE, ON, Aug. 16 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, is
pleased to provide an update on the progress of its North American clinical
trial with Mycobacterial Cell Wall-DNA Complex (MCC) - trademarked Urocidin -
in patients with non muscle-invasive bladder cancer that is refractory to the
current standard therapy. This indication was given Fast Track designation by
the U.S. Food and Drug Administration (FDA) in April of 2006.
    The Company commenced this trial in November, 2006. Since it had been
decided to work with opinion leaders and important medical institutions across
North America, there was some delay before all sites were given the go-ahead
to participate by their busy ethical committees and contract negotiators. An
investigators' meeting was held in April, 2007, and since then significant
progress has been made in the trial:

    -   The full complement of 25 sites has now been fully qualified to
        enroll patients and Bioniche's clinical team expects that the trial
        will be fully enrolled towards the end of calendar 2007. The targeted
        enrollment of this study is 105 patients which, coupled with
        additional safety information collected from a comparative trial,
        will allow full results to be reported one year after recruitment is
        completed for the efficacy and safety datasets. These results may
        also support regulatory submissions under FDA's Accelerated Approval

    -   On August 15, 2007 the first meeting of the Data Safety Monitoring
        Committee was held. The role of this independent body is to confirm
        that the safety of enrolled patients is being appropriately addressed
        and that, from an efficacy point of view, there is an appropriate
        basis for continuing the trial. After its meeting, the Committee has
        recommended that Bioniche "continue the trial unmodified until the
        next scheduled or triggered meeting." The next meeting of the
        Committee will be held in six months.

    Bioniche continues to work with regulators to optimize the design of its
second registration study in bladder cancer; a trial which will directly
compare the efficacy of Urocidin with the incumbent therapy for non
muscle-invasive bladder cancer. Progress on finalizing the design and
initiation of this trial will be reported as they are completed.
    Bioniche also continues to have discussions with potential development
and marketing partners, but as such discussions are under strict
confidentiality provisions, Bioniche is not in a position to provide an update
at this time.

    About MCC

    MCC is a sterile mycobacterial cell wall composition that has a dual mode
of action: immune stimulation and direct anticancer activity. It is formulated
as Urocidin(TM) for the treatment of bladder cancer, where it is administered
by the intravesical route directly into the bladder, coming into contact with
immune system cells and bladder cancer cells. MCC is also undergoing
preclinical evaluation as a treatment for peritoneal carcinomatosis associated
with colon and ovarian cancer.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
185 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. For more information, please visit

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF

For further information:

For further information: Jennifer Shea, Manager of Corporate
Communications & Investor Relations, Bioniche Life Sciences Inc., Telephone:
(613) 966-8058 ext. 1250, Cell: (613) 391-2097

Organization Profile

Telesta Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890